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Abstract 
Background: Pseudolarix kaempferi is a traditional Chinese natural product that possesses the potential cytotoxic 
effects against cancer. However, the precise molecular mechanism underlying its cytotoxic effects has not yet been 
completely elucidated. Here, we clarify the mechanism via which the ethanol extract of P. kaempferi (EEPK) leads to 
cytotoxicity mediated by apoptosis in mucoepidermoid carcinoma (MEC) originating from the salivary glands.
Methods: We investigated the mechanism underlying the anticancer efficacy of EEPK in human MEC in vitro by 
assessing mitochondrial dysfunction, mRNA levels, and morphological changes in apoptotic cell nuclei as well as by 
using a cytotoxicity assay, flow cytometric analysis, and western blotting.
Results: EEPK inhibited the growth of two human MEC cells and stimulated the induction of caspase‑mediated 
apoptosis that was accompanied by mitochondrial membrane depolarization. Compared with the vehicle control 
groups, EEPK decreased myeloid cell leukemia‑1 (Mcl‑1) expression in both cells whereas it significantly decreased 
B cell lymphoma‑2 (Bcl‑2) expression in MC3 cells only. The EEPK‑induced altered Mcl‑1 expression was caused by 
translational inhibition and proteasomal degradation. Additionally, EEPK significantly increased p‑Bcl‑2  (Ser70) expres‑
sion regardless of its total forms by facilitating the activation of the c‑Jun N‑terminal kinase (JNK) signaling pathway, 
which exhibited cell context dependency. Nevertheless, JNK activation following EEPK treatment was, at least in part, 
required for the proapoptotic efficacy of EEPK in both cells.
Conclusions: This study revealed that EEPK‑induced alterations of Mcl‑1 inhibition and JNK/Bcl‑2 phosphorylation 
cause apoptosis and provided basic preclinical data for future clinical trials regarding therapy for patients with MEC.
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Background
Natural products (NPs) are considered to have medicinal 
value because of their advantages including fewer side 
effects than synthetic drugs [1]. Hence, although there 
are numerous technical limitations in the traditional iso-
lation process for bioactive compounds, identifying bio-
active compounds for NP-based drug discovery in the 
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pharmaceutical industry has continuously been advanced 
by improved scientific techniques [2]. Furthermore, the 
Food and Drug Administration approves NP-based anti-
cancer drugs, and approximately 80 % of approved anti-
cancer drugs over the past few decades have been derived 
from NPs and their derivatives [3]. Therefore, NPs are a 
promising source for discovering novel anticancer drugs 
and should be further explored for developing effective 
therapeutic strategies with improved efficiency and mini-
mal toxicity. Pseudolarix kaempferi (also known as Pseu-
dolarix amabilis) has been used as a traditional Chinese 
medicine to treat fungal skin diseases [4]. The bioactive 
components in P. kaempferi root bark, twigs, and seeds 
chiefly comprise a series of diterpenoids, triterpenoids, 
or lignans that display antifungal, antimicrobial, and 
antiviral activities [4–6]. In particular, other components 
isolated from P. kaempferi have been shown to exert 
favorable anticancer effects including in vitro cytotoxic 
properties and proapoptotic activities [7, 8]. Although 
accumulating evidence has shown that P. kaempferi and 
P. kaempferi-derived components possess anticancer 
properties, the precise molecular mechanism that elicits 
the anticancer effects of P. kaempferi remains unclear.
B cell lymphoma-2 (Bcl-2) family proteins are clas-
sified into three subgroups based on their function and 
the presence of Bcl-2 homology (BH) domains (e.g., 
antiapoptotic and proapoptotic multidomains and proa-
poptotic BH3-only proteins). Bcl-2 proteins control the 
balance between life and death of cells by regulating 
mitochondrial outer membrane permeabilization, fol-
lowing which mitochondrial intermembrane space pro-
teins, such as cytochrome c and Smac, are released from 
mitochondria, thereby inducing caspase-mediated apop-
tosis [9]. Particularly, antiapoptotic Bcl-2 family proteins 
[e.g., Bcl-2, Bcl-xL, myeloid cell leukemia-1 (Mcl-1), and 
Bcl-W] protect cells from apoptosis by heterodimeriz-
ing with the proapoptotic Bcl-2 family protein Bax/Bak 
until being neutralized by BH3-only proteins; this phe-
nomenon is associated with carcinogenesis and poor 
susceptibility to chemotherapy [10]. These proteins share 
structural homology in four conserved BH domains, and 
targeting the BH3 or BH4 domains is considered as a 
promising strategy for cancer therapy [11, 12]. In particu-
lar, some agents derived from naturally occurring com-
pounds that target antiapoptotic Bcl-2 family proteins 
have been isolated and synthesized to identify further 
potent Bcl-2 inhibitors [13, 14]. Thus, discovering poten-
tial therapeutic inhibitors derived from naturally occur-
ring compounds that target antiapoptotic Bcl-2 family 
proteins might provide an effective therapeutic strategy 
for patients with cancer.
In the present study, we examined the molecular mech-
anism underlying the apoptotic cytotoxicity following 
treatment with the ethanol extract of P. kaempferi 
(EEPK), which was associated with the Mcl-1 inhibi-
tion in human mucoepidermoid carcinoma (MEC) cells 
caused by translation inhibition and proteasome-medi-
ated degradation. Additionally, EEPK stimulated the 
phosphorylation of Bcl-2 at the  Ser70 residue by activat-
ing the c-Jun N-terminal kinase (JNK) signaling path-
way in a cell context-dependent manner. Overall, these 
results supported the possibility that EEPK is a promising 




The root bark of P. kaempferi (553 g) was purchased from 
a herb store (Wonju, Republic of Korea) and extracted 
three times with ethanol (EtOH), under reflux, for 5  h. 
The extracted solution was filtered and evaporated under 
reduced pressure on a rotatory evaporator to produce 
18.6 g of EtOH extract. To fractionate the EtOH extract, 
it was suspended in  H2O and fractionated three times 
with hexane. The residual aqueous layer was further frac-
tionated three times with EtOAc. The EtOAc-soluble 
portion was concentrated to dryness to yield the EtOAc 
extract (5.78 g), which was dissolved in dimethyl sulfox-
ide (DMSO), aliquoted, and stored at − 20  °C. The final 
concentration of DMSO did not exceed 0.1 %.
Cell culture and reagents
Two cells of MEC originating from the salivary glands 
were used. MC3 cells were kindly provided by Prof. Wu 
Junzheng from the Fourth Military Medical University 
(Xi’an, China), and YD-15 cells were obtained from the 
Korean Cell Line Bank (Seoul, Republic of Korea). The 
cells were grown in DMEM/F12 or RPMI 1640 medium 
supplemented with 10 % fetal bovine serum and 1 % peni-
cillin/streptomycin in a humidified atmosphere incubator 
containing 5 %  CO2 at 37  °C. All experiments were per-
formed on cells cultured to 50–60 % confluence. All rea-
gents are listed in Additional file 1: Table S1.
Trypan blue exclusion assay
The cells were seeded in 6-well plates and incubated with 
various doses of EEPK for 24  h. Following cell detach-
ment by trypsinization, the cells were stained with 0.4 % 
trypan blue solution; thereafter the viable cells were 
counted using a hemocytometer.
Cell counting kit‑8 (CCK‑8) assay
Cells were seeded in 96-well plates and incubated with 
various doses of EEPK for 24  h. Subsequently, 10  µl of 
the CCK-8 solution was directly added to each well and 
mixed thoroughly with the culture media. Following 
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incubation at 37  °C for 2  h, the optical density of each 
well was measured using the Chameleon microplate 
reader (Hidex, Turku, Finland) at 450 nm.
DAPI staining
After being subjected to the designated treatment, the 
cells were fixed with 100 % EtOH at − 20 °C overnight and 
100 % MeOH at room temperature for 10 min. Thereafter, 
the fixed cells were placed onto slides and stained with 
2  µg/ml of DAPI solution. The morphological changes 
of the cells were observed under a fluorescence micro-
scope (Leica DMi8; Leica Microsystems GmbH, Wetzlar, 
Germany).
Annexin V‑FITC/PI double staining
To assess cells undergoing the early or late stages of 
apoptosis, the FITC-Annexin V Apoptosis Detection Kit 
was used according to the manufacturer’s instructions. 
The stained cells were analyzed using the FACSCalibur 
Flow Cytometer (BD Biosciences, San Jose, CA, USA) 
and the proportion of stained cells was quantified from 
10,000 cells per sample with BD CellQuest™ Pro soft-
ware. Annexin  V+/PI− staining indicates the early stage 
of apoptosis, whereas Annexin  V+/PI+ staining indicates 
the late stage of apoptosis. The flow cytometry data were 
reanalyzed using FlowJo software version 9/10 (FlowJo 
LLC, Ashland, OR, USA).
Analysis of the sub‑G1 population
Cells were fixed with 70 % EtOH overnight at − 20 °C fol-
lowed by incubation with 20 µg/ml of RNase A and pro-
pidium iodide solution for 15 min at 37 °C. The cell cycle 
distribution was detected using the FACSCalibur Flow 
Cytometer, and the proportion of stained cells was quan-
tified from 10,000 cells per sample with BD CellQuest™ 
Pro software. The relative percentages of each phase were 
reanalyzed using FlowJo software version 9/10.
Western blotting
Total proteins were extracted with RIPA lysis buffers 
including phosphatase inhibitor tablets and protease 
inhibitor cocktails. The protein concentrations in each 
sample were measured using the DC Protein Assay Kit. 
Following normalization, equal amounts of protein were 
separated using SDS-PAGE and then transferred to 
Immun-Blot® PVDF membranes. The membranes were 
blocked using 5 % skim milk in TBS with Tween 20 at 
room temperature for 2  h. Thereafter, they were incu-
bated overnight at 4  °C with primary antibodies. Subse-
quently, the membranes with primary antibodies were 
incubated with HRP-conjugated secondary antibodies 
for 2 h at room temperature. The antibodies of all target 
proteins are provided in Additional file 1: Table S2. The 
immunoreactive bands were visualized using WestGlow™ 
PICO PLUS Chemiluminescent substrate followed by 
ImageQuant™ LAS 500 (GE Healthcare Life Sciences, 
Piscataway, NJ, USA) or x-ray film.
Mitochondrial membrane potential (ΔΨm) assay
ΔΨm was measured by flow cytometry using the lipo-
philic fluorescent dye JC-1. Cells were harvested via 
trypsinization, washed with PBS, and pelleted via cen-
trifugation at 3500 rpm for 5 min. The pellets were resus-
pended in a 1× JC-1 working solution and incubated 
at 37  °C for 30  min in the dark. The stained cells were 
washed with a 1× assay buffer and pelleted via centrifu-
gation at 3500 rpm for 5 min. After removing the super-
natant, the cells were resuspended in a 1× assay buffer. 
Subsequently, the cells were transferred to FACS tubes 
and analyzed with the FACSCalibur Flow Cytometer. The 
proportion of stained cells was quantified from 10,000 
cells per sample with BD CellQuest™ Pro software. The 
data were reanalyzed using FlowJo software.
Cytosolic and mitochondrial fractions
Cytosolic and mitochondrial fractions were isolated with 
the Mitochondria/Cytosol Fractionation Kit. Briefly, cells 
were washed with ice-cold PBS, and the cell pellet was 
resuspended in a 1× cytosol extraction buffer mix con-
taining DTT and protease inhibitor for 10  min on ice. 
Following centrifugation at 13,000  rpm for 15  min at 
4 °C, the supernatants containing cytosolic proteins were 
collected, and the pellets were resuspended in a mito-
chondrial extraction buffer mix. The supernatant con-
taining mitochondrial proteins was collected from the 
final centrifugation.
Quantitative real‑time PCR (qPCR)
Total RNA was extracted using TRIzol Reagent. Total 
RNA (1  µg) was reverse-transcribed using the AMPI-
GENE cDNA Synthesis Kit; the resultant cDNA was sub-
jected to PCR using the AMPIGENE qPCR Green Mix 
Hi-Rox. The qPCR instrument was assembled using the 
Applied Biosystems StepOnePlus Real-Time PCR System 
(Applied Biosystems, Foster City, CA, USA), and PCR 
conditions for all genes were as follows: 95 °C for 2 min, 
followed by 40 cycles of 95 °C for 10 s and 60 °C for 30 s. 
The relative amount of Mcl-1 expression was normal-
ized to the amount of GAPDH expression and calculated 
using the  2−∆∆Ct method. The qPCR primers of all the 
target genes are listed in Additional file 1: Table 3.
Statistical analysis
All data were transformed using GraphPad Prism ver-
sion 7.0 (La Jolla, CA, USA). Statistical analyses were per-
formed using SPSS version 22.0 (SPSS Inc., Chicago, IL, 
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USA). Two-tailed Student’s t-tests for two comparisons 
or one-way ANOVA with Tukey’s post hoc test for mul-
tiple comparisons were used; p values of < 0.05 were con-
sidered statistically significant.
Results
EEPK inhibits the growth and stimulates the induction 
of apoptosis in human MEC cells
To ascertain the potentially cytotoxic effect of EEPK on 
human MEC cells, we first conducted dose–response 
tests using a trypan blue exclusion assay and CCK-8 
assay after treatment with various doses of EEPK. It was 
observed that EEPK significantly decreased the growth 
of two human MEC cells in a dose-dependent manner 
(Fig. 1a, b). To determine whether the cytotoxic effect of 
EEPK on human MEC cells was related to apoptosis, the 
cells were stained with DAPI solution to detect chromatin 
condensation and DNA fragmentation, the typical mor-
phological characteristics of apoptotic cells. Abundant 
visualization of distinctively compacted chromosome or 
DNA fragments was achieved following EEPK treatment 
(Fig. 1c). We further investigated the apoptotic effect of 
EEPK using flow cytometric analysis. Compared with 
the vehicle control groups, the rate of Annexin  V+ cells 
undergoing early-stage (Annexin  V+/PI−) or late-stage 
(Annexin  V+/PI+) apoptosis was apparently increased 
following EEPK treatment (Fig. 1d). Accordingly, a signif-
icant accumulation of apoptotic cells in the sub-G1 phase 
was observed in the EEPK-treated cells (Fig. 1e). To fur-
ther corroborate EEPK-induced apoptosis, we evaluated 
the expression of apoptosis marker proteins via western 
blotting and observed an abundant cleavage of caspase 9, 
caspase 3, and PARP in a dose-dependent manner follow-
ing EEPK treatment (Fig.  1f ). Collectively, these results 
indicated that EEPK inhibits the growth and stimulates 
the induction of apoptosis via a caspase-mediated path-
way in human MEC cells.
EEPK decreases Mcl‑1 and Bcl‑2 protein levels to 
facilitate apoptosis following mitochondrial membrane 
depolarization
To investigate whether the EEPK-induced apoptosis 
in human MEC cells was accompanied by mitochon-
drial dysfunction, the cationic dye JC-1 that can detect 
changes in mitochondrial membrane potential was used. 
Compared with the vehicle control groups, the mono-
meric form of JC-1 (cytosolic green fluorescence) was 
increased in the EEPK-treated groups (Fig. 2a), implying 
a disrupted mitochondrial membrane potential. Addi-
tionally, EEPK caused the release of cytochrome c from 
the mitochondria into the cytosol (Fig. 2b). To determine 
the key molecules underlying mitochondrial membrane 
depolarization following EEPK treatment, we detected 
antiapoptotic Bcl-2 family proteins, which regulate 
mitochondrial dysfunction followed by the induction of 
apoptosis. Significantly decreased Mcl-1 expression was 
observed in two human MEC cells, whereas significantly 
decreased Bcl-2 expression was observed in only the 
MC3 cells (Fig. 2c). Conversely, EEPK showed no appar-
ent effect on Bcl-xL expression in both cells (Additional 
file 1: Fig. S1). Taken together, these results indicated that 
EEPK results in mitochondrial membrane depolarization 
and cytochrome c release accompanied by the decreased 
expression of negative regulators of apoptosis, such as 
Mcl-1 and Bcl-2 proteins, in human MEC cells.
Mcl‑1 downregulation induced by EEPK is accomplished 
by translation inhibition and proteasome‑mediated 
degradation
To examine any dose-dependent effect of EEPK on 
Mcl-1 mRNA levels in human MEC cells, we per-
formed qPCR. EEPK had no significant effect on Mcl-1 
mRNA levels in either cell line (Fig. 3a), indicating the 
possibility of translational or posttranslational regula-
tion of Mcl-1. To clarify whether the decrease in Mcl-1 
protein levels induced by EEPK treatment was caused 
by its translational inhibition, we examined the phos-
phorylation status of eIF4E, a translation initiation 
factor. As shown in Fig. 3b, compared with the vehicle 
control groups, EEPK resulted in an apparent decrease 
of p-eIF4E expression in both cells. To further inves-
tigate whether EEPK could regulate the stability of 
Mcl-1, we used cycloheximide (CHX) to block new 
protein synthesis. Mcl-1 expression in the EEPK- and 
CHX-treated groups was more reduced than in the 
CHX-treated groups (Fig.  3c). Furthermore, pretreat-
ment with MG132, a potent proteasome inhibitor, res-
cued the EEPK-induced decrease in Mcl-1 expression 
(Fig. 3d). These results indicated that EEPK facilitates 
the decrease in Mcl-1 protein levels via the induction 
Fig. 1 Cytotoxic and apoptotic effects of EEPK on human MEC cells. MC3 and YD‑15 cells were treated with DMSO or various doses of EEPK (7.5, 
15, and 30 µg/ml for MC3 and 10, 20, and 40 µg/ml for YD‑15) for 24 h. The cytotoxic effect of EEPK was determined by trypan blue exclusion assay 
(a) and CCK‑8 assay (b). c Representative images of DAPI‑stained human MEC cells (magnification, 400×). The white arrows indicate apoptotic cells. 
Scale bar, 50 μm. d Annexin V/PI double staining was assessed using FACS analysis. e The population of sub‑G1 in human MEC cells with or without 
EEPK. f Western blot images showing the expression levels of c‑caspase 9, c‑caspase 3, and c‑PARP. β‑actin was used as an internal control. All bar 
graphs represent the mean ± SD of three independent experiments. *p < 0.05
(See figure on next page.)
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Fig. 1 (See legend on previous page.)
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of translational inhibition and proteasome-mediated 
degradation, suggesting that Mcl-1 downregulation via 
translation inhibition and proteasomal degradation is 
an important event for apoptosis of human MEC cells 
following EEPK treatment.
EEPK induces phosphorylated Bcl‑2 (Ser70) by activating 
the JNK signaling pathway
To examine the contribution of EEPK to Bcl-2 phos-
phorylation, we evaluated Bcl-2 phosphorylation at 
the serine 70 residue in human MEC cells following 
EEPK treatment. EEPK significantly increased p-Bcl-2 
 (Ser70) expression in both cells compared with that in 
the vehicle control groups (Fig.  4a). To investigate the 
Fig. 2 Effect of EEPK on disrupted mitochondrial membrane potential, cytochrome c release, and antiapoptotic Bcl‑2 family proteins. MC3 and 
YD‑15 cells were treated with DMSO or the indicated doses of EEPK for 24 h. a Measurement of mitochondrial membrane potential in human MEC 
cells with or without EEPK using a JC‑1 probe. Bar graphs represent the mean ± SD of three independent experiments. *p < 0.05. b Cytochrome c 
release into the cytosol was evaluated using cytosolic and mitochondrial fractions. Cox IV and α‑tubulin were used as specific fraction markers for 
mitochondria and cytosol, respectively. Data are representative of two independent experiments. c Western blot images showing the expression 
levels of Mcl‑1 and Bcl‑2. β‑actin was used as an internal control. All bar graphs represent the mean ± SD of three independent experiments. 
*p < 0.05
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involvement of the mitogen-activated protein kinase 
signaling pathway in EEPK-induced Bcl-2 phospho-
rylation, the phosphorylated forms of JNK, p38, and 
ERK1/2 in both cells following EEPK treatment were 
detected with their corresponding total forms. Com-
pared with p-JNK expression levels in the vehicle 
control groups, those after EEPK treatment were con-
sistently induced in both cells in which the basal levels 
of total JNK remained unchanged (Fig. 4b). Conversely, 
no consistent dose-dependent effect on the expression 
levels of p-p38 or p-ERK1/2 was observed in either cell 
line following EEPK treatment (Additional file  1: Fig. 
S2). To elucidate the role of JNK activation on EEPK-
induced Bcl-2 phosphorylation, we used the potent 
reversible JNK inhibitor SP600125. Compared with 
EEPK treatment alone, the addition of SP600125 before 
EEPK treatment modestly abolished Bcl-2 phospho-
rylation at the  Ser70 residue only in the MC3 cell line 
(Fig.  4c). Collectively, these data suggested that JNK 
activation following EEPK treatment is required for 
Bcl-2 phosphorylation at the  Ser70 residue in human 
MEC cells in a cell context-dependent manner.
Fig. 3 Effect of EEPK on Mcl‑1 protein turnover in human MEC cells. a MC3 and YD‑15 cells were treated with DMSO or the indicated doses of EEPK 
for 24 h. Relative mRNA levels of Mcl-1 in EEPK‑induced human MEC cells were assessed using qPCR and normalized to GAPDH. Data are shown 
as the mean ± SD of three independent experiments. b The protein levels of p‑eIF4E were examined with western blotting. β‑actin was used as 
an internal control. All bar graphs represent the mean ± SD of three independent experiments. *p < 0.05. c Both cells were pretreated with the 
indicated doses of CHX for 1 h in the absence or presence of EEPK for 24 h. Representative western blot images for Mcl‑1 expression. d Pretreatment 
with the indicated doses of MG132 for 1 h in the absence or presence of EEPK for 24 h. The protein levels of Mcl‑1 were determined via western 
blotting. β‑actin was used as an internal control. All bar graphs represent the mean ± SD of three independent experiments. *p < 0.05; #p < 0.05
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JNK activation is responsible for EEPK‑induced apoptosis
To define the contribution of JNK activation on EEPK-
induced apoptosis, MC3 and YD-15 cells were pre-
treated with SP600125 to detect altered PARP cleavage. 
Following EEPK treatment, SP600125 partly abrogated 
the abundant cleavage of PARP in both cells (Fig.  5a) 
and reduced the proportion of apoptotic cells (Fig. 5b). 
Furthermore, compared with EEPK treatment alone, 
cotreatment with SP600125 displayed less compacted 
chromosome or DNA fragments (Fig.  5c). Taken 
together, these data suggested that JNK activation can 
be a critical event for modulating apoptosis in human 
MEC cells following EEPK treatment.
Discussion
MEC is the most commonly diagnosed tumor of the 
salivary glands and is composed of three different cell 
types: mucinous, epidermoid, and intermediated cells 
[15]. Typically, in cases of salivary gland tumors, severe 
side effects can occur postoperatively, including per-
manent facial nerve paralysis from infiltration of the 
facial nerve and varying degrees of xerostomia [16, 17]. 
Furthermore, it is extremely difficult to predict the dis-
ease progression because of its anatomically complex 
and varied pathological forms. To solve this issue, stud-
ies have investigated novel approaches for the diagnosis 
and treatment of salivary gland tumors (that have several 
genetic alterations); however, there have been no notable 
achievements. Therefore, novel and effective therapeutic 
options for patients with MEC are needed. In the present 
study, we provided a promising chemotherapeutic option 
for patients with MEC by demonstrating the apoptosis 
induced by EEPK and its predicted oncological targets.
Mcl-1, a member of the antiapoptotic Bcl-2 pro-
tein family, is highly expressed in various tumor types 
and is associated with poor prognoses and poor clini-
cal outcomes owing to tumor resistance to anticancer 
drugs [18]. In response to various extracellular stimuli 
Fig. 4 Effect of EEPK on phosphorylated Bcl‑2  (Ser70) through the activation of the JNK signaling pathway. MC3 and YD‑15 cells were treated with 
DMSO or indicated doses of EEPK for 24 h. a Western blot images showing p‑Bcl‑2  (Ser70) expression levels. b The p‑JNK and JNK expression levels 
were analyzed with western blotting. β‑actin was used as an internal control. c Both cells were pretreated with the indicated doses of SP600125 
for 1 h and then treated with DMSO or EEPK for 24 h. Representative western blot images showing the expression levels of p‑JNK, JNK, and p‑Bcl‑2 
 (Ser70). β‑actin was used as an internal control. All bar graphs represent the mean ± SD of three independent experiments. *p < 0.05; #p < 0.05
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including cytokines and growth factors, Mcl-1 expression 
levels are thoroughly controlled via multiple processes 
such as transcriptional, posttranscriptional, and post-
translational regulation [19], thereby determining cancer 
cell survival or death. In the present study, we observed 
that Mcl-1 inhibition in human MEC cells following 
EEPK treatment was not caused by altered Mcl-1 mRNA 
levels. Therefore, we excluded the possibility that Mcl-1 
expression was regulated at the transcriptional level upon 
EEPK treatment. Previous studies have reported that 
translational inhibition of Mcl-1 expression in response 
to naturally occurring compounds attributes to the 
induction of  G2/M cell cycle arrest or apoptosis in sev-
eral cancer cells, which was involved in the phosphoryla-
tion status of translation initiation factors such as eIF4E 
or eIF4G [20, 21]. In the present study, we observed an 
apparent decrease in the phosphorylated levels of eIF4E, 
suggesting that the EEPK-induced inhibition of eIF4E 
phosphorylation contributes to the decrease in Mcl-1 
protein levels. Reportedly, the posttranslational modifi-
cation of Mcl-1 is accompanied by ubiquitination, cleav-
age, and phosphorylation, which decides the protein 
turnover, localization, and function [22]. In particular, 
our previous findings have shown that Mcl-1 inhibition 
Fig. 5 Contribution of JNK activation on apoptosis induced by EEPK. MC3 and YD‑15 cells were pretreated with the indicated doses of SP600125 
for 1 h and then treated with DMSO or EEPK for 24 h. a Western blotting was performed to detect the expression levels of cleaved PARP. β‑actin 
was used as an internal control. b Annexin V/PI double staining was measured by FACS analysis. c Representative images of DAPI‑stained cells 
(magnification, 400×). The white arrows indicate apoptotic cells. Scale bar, 20 μm. All bar graphs represent the mean ± SD of three independent 
experiments. *p < 0.05; #p < 0.05
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induced by naturally occurring compounds in oral cancer 
cells is involved in lysosome- or proteasome-dependent 
degradation [23, 24]. These results led us to speculate 
that EEPK may cause a rapid turnover of Mcl-1 pro-
tein in human MEC cells. The results from our present 
study have clearly revealed that MG132-induced protea-
somal inhibition restored the EEPK-induced decrease in 
Mcl-1 expression. Therefore, the EEPK-induced Mcl-1 
reduction was clearly caused by translation inhibition 
and proteasome-dependent degradation rather than by 
changing mRNA levels. It was previously suggested that 
the rapid turnover of Mcl-1 protein depends on its phos-
phorylation by several kinases including GSK3, which is 
closely related to the activity of E3 ubiquitin ligases [25, 
26]. Thus, future studies should focus on identifying the 
upstream target molecules (e.g., kinases or E3 ubiquitin 
ligases) that result in a rapid turnover of Mcl-1 protein in 
human MEC cells.
A previous study reported that medicinal plant 
extracts, such as those of Vernonia condensata con-
tribute toward triggering intrinsic apoptotic pathway, 
as indicated by disruption of mitochondrial membrane 
potential and induction of proapoptotic Bcl-2 fam-
ily protein [27]. In the present study, we observed that 
EEPK had no effect on Bcl-2 expression in YD-15 cells, 
despite the decreased Bcl-2 expression in MC3 cells. 
It has been reported that the ability of Bcl-2 to protect 
cells from apoptosis could be regulated by its posttrans-
lational modification, such as phosphorylation, occur-
ring in four serine/threonine residues  (Thr56,  Thr69, 
 Ser70, and  Ser87) within the loop domain [28, 29]. Bcl-2 
protein phosphorylation triggers the inactivation and 
degradation of the protein [30, 31]. Although specula-
tions regarding the biological function of Bcl-2 phos-
phorylation have been controversial, it is certain that 
Bcl-2 phosphorylation at the  Ser70 residue is important 
and frequently occurs in several cancer types following 
exposure to microtubule-targeting drugs [32]. In par-
ticular, patients with colorectal adenocarcinoma with-
out p-Bcl-2  (Ser70) expression exhibit shorter survival 
rates than patients with positive p-Bcl-2  (Ser70) expres-
sion, which is correlated with lymph node metastasis 
and clinical stages [33]. Considering the critical role of 
Bcl-2 phosphorylation at the  Ser70 residue, we inves-
tigated p-Bcl-2  (Ser70) expression levels induced by 
EEPK in human MEC cells. The results clearly showed 
that EEPK increased p-Bcl-2  (Ser70) expression levels 
in both cells in a dose-dependent manner unlike the 
cell context-dependent response of total Bcl-2 levels. 
A previous study reported that Bcl-2 phosphorylation 
disrupts the interaction between Bcl-2 and Bax, facili-
tating Bax release and the subsequent induction of 
apoptosis [34]. Therefore, we cautiously speculated that 
the increased p-Bcl-2  (Ser70) expression in human MEC 
cells following EEPK treatment may primarily contrib-
ute to the induction of apoptosis by terminating inter-
actions between p-Bcl-2 and its binding partners, such 
as the proapoptotic Bcl-2 family protein Bax, rather 
than by decreasing total Bcl-2 protein. Additional stud-
ies are required to elucidate the interactions of Bcl-2 
binding partners.
Among the three mitogen-activated protein kinases, 
JNK plays a key role in facilitating the apoptosis signaling 
pathway in response to both extracellular and intracel-
lular stress stimuli [35]. JNK phosphorylation at residues 
Thr183 and Tyr185 induced by two upstream mitogen-
activated protein kinase kinase typically regulates the 
activation of specific downstream target molecules; this 
is responsible for various cellular activities, including 
apoptosis, proliferation, migration, survival, differentia-
tion, and inflammation [36]. It was previously reported 
that the activation of the JNK signaling pathway is suffi-
cient to phosphorylate Bcl-2 at both residues  Ser70 and 
 Thr56, thereby inducing apoptosis in prostate cancer 
in vitro [37–39]. In the present study, we observed that 
EEPK stimulated the activation of the JNK signaling 
pathway in both cells in a dose-dependent manner, indi-
cating that the activated JNK signaling pathway partici-
pates in Bcl-2 phosphorylation. Further, we investigated 
the involvement of the JNK signaling pathway on Bcl-2 
phosphorylation at the  Ser70 residue. SP600125, a potent 
reversible inhibitor of JNK, suppressed p-Bcl-2  (Ser70) 
expression levels in EEPK-treated MC3 cells. However, 
Bcl-2 phosphorylation in EEPK-treated YD-15 cells was 
not influenced by SP600125, although the activated JNK 
signaling pathway was completely inhibited. Remarkably, 
SP600125 significantly abrogated EEPK-induced apop-
tosis in both MC3 and YD-15 cells regardless of p-Bcl-2 
expression. It appears that EEPK-induced Bcl-2 phos-
phorylation may be one of the molecular mechanisms 
leading to apoptosis in human MEC cells. As described 
above, the activation of the JNK signaling pathway con-
tributes to the phosphorylation of several downstream 
targets including c-Jun, ATF, and STAT3 [36]. Therefore, 
we presumed that JNK activation might regulate other 
downstream targets, thereby stimulating proapoptotic 
activity in human MEC cells; these targets should be 
investigated in the future. Nevertheless, we believe that 
our data revealed the basic molecular mechanism via 
which EEPK, at least in part, phosphorylates Bcl-2 pro-
tein at the  Ser70 residue; namely, by activating the JNK 
signaling pathway and thereby inducing apoptosis in 
human MEC cells.
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Conclusions
The results of the present study demonstrated that 
EEPK promotes apoptosis by targeting Mcl-1 and the 
JNK/Bcl-2 signaling pathway, which, in turn, inhibits 
the growth of human MEC cells. These findings provide 
molecular insight into the potential anticancer efficacy of 
EEPK, thereby contributing to the development of future 
human MEC therapeutics.
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